November 17, 2014

Artery will present two posters at American Heart Association's Scientific Sessions 2014 in Chicago. John Bielicki's oral abstract presented at ATVB will be presented by Jan Johansson as a poster at the "Best of AHA Specialty Conferences: ATVB 2014" session and titled "ABCA1 Ligand Peptides That Stimulate Cellular Cholesterol Efflux With High Potency Increase Insulin Sensitivity in Metabolic and Genetic Mouse Models of Obesity and Type 2 Diabetes." 

 

The second poster will be presented by Anouar Hafiane, McGill Univ, Montreal, QC, Canada and titled "Novel Apolipoprotein E-derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport in vitro and Induces de novo Formation of Apoa-I Containing preβ-1 HDL in Human Plasma."

 

August 31, 2014

Jan Johansson will present a moderated poster titled "The ABCA1 agonist CS-6253 generates functional nascent HDL particles resulting in efficient cholesterol SR-BI delivery to hepatic cells and shows macrophage specific cholesterol mobilization and atherosclerosis reduction in apoE KO mice" at European Society of Cardiology 2014. 

 

Session Title: Lipid lowering treatment: new findings

Presentation Date &Time: August 31, 2014 at 16.04 (4.04 pm)

Location:  Moderated poster corner - Central Village, Congress centre, Barcelona, Spain​

 

August 4, 2014

John Bielicki's oral abstract presented at ATVB titled "ABCA1 Ligand Peptides That Stimulate Cellular Cholesterol Efflux With High Potency Increase Insulin Sensitivity in Metabolic and Genetic Mouse Models of Obesity and Type 2 Diabetes" was among the top 10 percent of the accepted abstracts and has been selected to re-present at AHA Scientific Sessions 2014. 

 

Session Title: Best of AHA Specialty Conferences: ATVB 2014 

Session Date: Monday, November 17, 2014 

Presentation Time: 9:30-11:00 AM

Location: Poster Hall, Best of AHA Specialty Conference, McCormick Convention Center, Chicago, IL.

 

July 16, 2014

Jan Johansson will present a poster at Alzheimer’s Association International Conference 2014 (AAIC), with title Cogpep™, ApoE derived ABCA1 Agonist Peptides Reverse Alzheimer’s Disease Phenotype in Human ApoE4 Target Replacement Mice. The poster number is P4-362.

​​

​The event will be held at Bella Center Convention Center in Copenhagen, Denmark.

 

June 15, 2014

John Bielicki's poster titled "Novel ABCA1 Ligand Peptides Based on the C-Terminal Lipid Binding Domain of ApolipoproteinE Increase Insulin Sensitivity in Metabolic and Genetic Mouse Models of Obesity and Type 2 Diabetes" will be published at The American Diabetes Association's 74th Scientific Sessions. The abstract number is 2392-PO and will be available from Sunday morning.

 

The event will be held at Moscone Center in San Francisco, CA, USA.​​

May 23, 2014

Has ApoE’s Time Come as a Therapeutic Target? ALZFORUM.COM, Research News:

Artery Therapeutics' collaboration with Dr. Daniel Michaelson at Tel Aviv University was published online in an article that discusses ApoE4 allele and ApoE as a Therapeutic Target. Study results will be presented in Copenhagen for Alzheimer’s Association International Conference in July 2014.

 

http://www.alzforum.org/news/research-news/has-apoes-time-come-therapeutic-target

 

May 2 & 4, 2014

John Bielicki will present both an oral abstract and poster at Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions 2014  (ATVB 2014) in Toronto, Canada. He will also give a speech at the 2014 Workshop on HDL Structure that is immediately after ATVB 2014 conference.

 

All events will be held in Sheraton Centre Toronto Hotel, ON, Canada.

January 8, 2014

Artery Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2014 Conference on Tuesday, January 14th at 3:45 pm. 

 

The event will be held in Parc 55, Track: A - Hearst (4th Floor), San Francisco, CA, USA.

 

Copyright © Artery Therapeutics, Inc. All rights reserved.